Anika Therapeutics (ANIK) Tax Provisions (2010 - 2026)

Anika Therapeutics (ANIK) has reported Tax Provisions for 17 consecutive years, with $100000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions fell 85.71% year-over-year to $100000.0 in Q2 2026; TTM through Jun 2026 was -$2.4 million, a 143.24% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 132.22% from the prior year.
• Tax Provisions was $100000.0 for Q2 2026 at Anika Therapeutics, down from $235000.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $9.1 million in Q4 2023 and troughed at -$3.7 million in Q4 2025.
• A 5-year average of $846555.6 and a median of $100000.0 in 2025 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions plunged 271.43% in 2022 and jumped 540.0% in 2024, its largest moves.
• Over 5 years, Tax Provisions stood at $6.6 million in 2022, then jumped by 37.62% to $9.1 million in 2023, then sank by 72.24% to $2.5 million in 2024, then tumbled by 245.07% to -$3.7 million in 2025, then jumped by 102.73% to $100000.0 in 2026.
• The last three Tax Provisions figures came in at $100000.0 (Q2 2026), $235000.0 (Q1 2026), and -$3.7 million (Q4 2025), per Business Quant data.